Overview

Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety of Besivance (besifloxacin ophthalmic suspension, 0.6%) compared to vehicle.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch & Lomb Incorporated
Treatments:
7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Besifloxacin
Fluoroquinolones